NanoSphere Health Sciences Inc. (NSHS.CN)
CAD 0.06
(-7.69%)
CAD 0.06
(-7.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 220.07 Thousand USD | -99.92% |
| 2022 | 283.87 Thousand USD | -26.46% |
| 2021 | 386 Thousand USD | -31.76% |
| 2020 | 565.62 Thousand USD | -83.66% |
| 2019 | 3.46 Million USD | -25.38% |
| 2018 | 4.63 Million USD | 322.31% |
| 2017 | 1.09 Million USD | 76.6% |
| 2016 | 621.86 Thousand USD | 436.32% |
| 2015 | 115.95 Thousand USD | -34.98% |
| 2014 | 178.33 Thousand USD | -83.64% |
| 2013 | 1.08 Million USD | -57.72% |
| 2012 | 2.57 Million USD | -17.05% |
| 2011 | 3.1 Million USD | 1471.59% |
| 2010 | 197.71 Thousand USD | 27.82% |
| 2009 | 154.68 Thousand USD | -54.57% |
| 2008 | 340.52 Thousand USD | -70.72% |
| 2007 | 1.16 Million USD | 2754.71% |
| 2006 | 40.74 Thousand USD | 41.24% |
| 2005 | 28.84 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 32.01 Thousand USD | 58164.02% |
| 2024 Q2 | 56.71 Thousand USD | 62.64% |
| 2023 Q3 | 52.67 Thousand USD | -21.41% |
| 2023 Q2 | 67.02 Thousand USD | 24.73% |
| 2023 Q1 | 53.73 Thousand USD | -53.88% |
| 2023 Q4 | 54.94 USD | -99.9% |
| 2023 FY | 228.13 USD | -99.92% |
| 2022 Q2 | 75.94 Thousand USD | 3.91% |
| 2022 FY | 283.87 Thousand USD | -26.46% |
| 2022 Q4 | 116.51 Thousand USD | 535.46% |
| 2022 Q3 | 18.33 Thousand USD | -75.85% |
| 2022 Q1 | 73.08 Thousand USD | -17.33% |
| 2021 FY | 386 Thousand USD | -31.76% |
| 2021 Q1 | 69.79 Thousand USD | -55.01% |
| 2021 Q2 | 145.9 Thousand USD | 109.05% |
| 2021 Q3 | 81.91 Thousand USD | -43.86% |
| 2021 Q4 | 88.39 Thousand USD | 7.92% |
| 2020 Q1 | 226.63 Thousand USD | -78.8% |
| 2020 Q2 | 115.69 Thousand USD | -48.95% |
| 2020 Q3 | 68.15 Thousand USD | -41.09% |
| 2020 Q4 | 155.13 Thousand USD | 127.62% |
| 2020 FY | 565.62 Thousand USD | -83.66% |
| 2019 FY | 3.46 Million USD | -25.38% |
| 2019 Q4 | 1.06 Million USD | 23.95% |
| 2019 Q3 | 862.34 Thousand USD | 64.23% |
| 2019 Q2 | 525.09 Thousand USD | -47.74% |
| 2019 Q1 | 1 Million USD | -34.92% |
| 2018 Q2 | 1.01 Million USD | 1.67% |
| 2018 FY | 4.63 Million USD | 322.31% |
| 2018 Q4 | 1.54 Million USD | 42.78% |
| 2018 Q3 | 1.08 Million USD | 6.55% |
| 2018 Q1 | 998.12 Thousand USD | 25.7% |
| 2017 Q1 | 73.72 Thousand USD | -12.29% |
| 2017 FY | 1.09 Million USD | 76.6% |
| 2017 Q4 | 794.06 Thousand USD | 794.33% |
| 2017 Q3 | 88.78 Thousand USD | -31.63% |
| 2017 Q2 | 129.85 Thousand USD | 76.15% |
| 2016 Q1 | 24.58 Thousand USD | 2.5% |
| 2016 FY | 621.86 Thousand USD | 436.32% |
| 2016 Q3 | 464.73 Thousand USD | 836.9% |
| 2016 Q2 | 49.6 Thousand USD | 101.75% |
| 2016 Q4 | 84.05 Thousand USD | -81.91% |
| 2015 Q2 | 40.35 Thousand USD | 21.83% |
| 2015 Q4 | 23.98 Thousand USD | 2.6% |
| 2015 Q3 | 23.37 Thousand USD | -42.06% |
| 2015 FY | 115.95 Thousand USD | -34.98% |
| 2015 Q1 | 33.11 Thousand USD | 118.76% |
| 2014 Q4 | -176.56 Thousand USD | -174.48% |
| 2014 Q1 | 56.81 Thousand USD | -73.75% |
| 2014 FY | 178.33 Thousand USD | -83.64% |
| 2014 Q2 | 64.42 Thousand USD | 13.38% |
| 2014 Q3 | 237.05 Thousand USD | 267.96% |
| 2013 Q3 | 169.76 Thousand USD | -53.97% |
| 2013 Q4 | 216.42 Thousand USD | 27.48% |
| 2013 FY | 1.08 Million USD | -57.72% |
| 2013 Q1 | 332.01 Thousand USD | -42.57% |
| 2013 Q2 | 368.83 Thousand USD | 11.09% |
| 2012 FY | 2.57 Million USD | -17.05% |
| 2012 Q2 | 823.17 Thousand USD | 51.26% |
| 2012 Q3 | 597.12 Thousand USD | -27.46% |
| 2012 Q4 | 578.07 Thousand USD | -3.19% |
| 2012 Q1 | 544.19 Thousand USD | -28.54% |
| 2011 FY | 3.1 Million USD | 1471.59% |
| 2011 Q4 | 761.55 Thousand USD | 24.63% |
| 2011 Q2 | 812.33 Thousand USD | -22.33% |
| 2011 Q1 | 1.04 Million USD | 1256.59% |
| 2011 Q3 | 611.06 Thousand USD | -24.78% |
| 2010 FY | 197.71 Thousand USD | 27.82% |
| 2010 Q4 | 77.1 Thousand USD | 58.04% |
| 2010 Q3 | 48.78 Thousand USD | 26.02% |
| 2010 Q2 | 38.71 Thousand USD | 18.49% |
| 2010 Q1 | 32.67 Thousand USD | 5.04% |
| 2009 Q1 | 37.37 Thousand USD | 100.61% |
| 2009 Q2 | 43.28 Thousand USD | 15.8% |
| 2009 Q3 | 32.41 Thousand USD | -25.11% |
| 2009 Q4 | 31.1 Thousand USD | -4.05% |
| 2009 FY | 154.68 Thousand USD | -54.57% |
| 2008 Q2 | 137.83 Thousand USD | 17.92% |
| 2008 Q3 | 6.26 Million USD | 4442.23% |
| 2008 FY | 340.52 Thousand USD | -70.72% |
| 2008 Q4 | -6.16 Million USD | -198.51% |
| 2008 Q1 | 116.88 Thousand USD | -84.9% |
| 2007 Q1 | 4444.35 USD | -73.63% |
| 2007 Q3 | 291.09 Thousand USD | 245.13% |
| 2007 Q4 | 774.26 Thousand USD | 165.98% |
| 2007 Q2 | 84.34 Thousand USD | 1797.8% |
| 2007 FY | 1.16 Million USD | 2754.71% |
| 2006 Q3 | 5606.30 USD | -10.95% |
| 2006 Q1 | 11.48 Thousand USD | 81.67% |
| 2006 FY | 40.74 Thousand USD | 41.24% |
| 2006 Q2 | 6296.00 USD | -45.2% |
| 2006 Q4 | 16.85 Thousand USD | 200.68% |
| 2005 Q4 | 6323.53 USD | -71.61% |
| 2005 Q3 | 22.27 Thousand USD | 0.0% |
| 2005 FY | 28.84 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 95.761% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 97.157% |
| BetterLife Pharma Inc. | 3.24 Million CAD | 93.208% |
| BioVaxys Technology Corp. | 2.4 Million CAD | 90.84% |
| ChitogenX Inc. | 2.83 Million CAD | 92.223% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 94.771% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 98.261% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | 61.001% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 95.673% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -755.835% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | 67.382% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | 81.917% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -205.295% |
| MYND Life Sciences Inc. | 1.47 Million CAD | 85.077% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | 81.695% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | 92.77% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | 77.15% |
| Telescope Innovations Corp. | 6.35 Million CAD | 96.535% |